BRAF as a target for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• BRAF mutations drive tumor growth via the MAPK pathway, presenting therapeutic targets.
• BRAF V600 mutations are prevalent in melanoma, thyroid, and colorectal cancers.
• Targeting BRAF offers a promising strategy for oncogene-targeted cancer therapy.

Purpose of the Study:

• To review preclinical and clinical data on BRAF inhibitors.
• To discuss the development of selective BRAF inhibitors.
• To explore resistance mechanisms and strategies to overcome them.

Main Methods:

• Review of preclinical studies on BRAF inhibitors in cell lines and animal models.
• Analysis of drug development from non-selective to selective BRAF inhibitors (e.g., PLX4032, GSK2118436).
• Examination of clinical efficacy, toxicity, and resistance mechanisms.

Main Results:

• BRAF inhibitors show antitumor activity, with context-dependent MAPK pathway modulation.
• Selective BRAF inhibitors demonstrate clinical efficacy in BRAF V600 mutant melanomas.
• Mechanisms of resistance exist, necessitating strategies to overcome them.

Conclusions:

• BRAF inhibitors are a key therapeutic strategy for BRAF-mutant cancers.
• Understanding resistance is crucial for sustained clinical benefit.
• Ongoing research focuses on optimizing BRAF inhibitor therapy and overcoming resistance.